Last reviewed · How we verify
pep2dia
At a glance
| Generic name | pep2dia |
|---|---|
| Sponsor | Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparing the Effect of Metformin vs. Pep2dia as an Adjunct to Letrozole on Ovulation Induction and Pregnancy Outcomes in Overweight Women With PCOS (EARLY_PHASE1)
- Clinical Study to Assess the Long-term Effect of Pep2Dia® on Glucose Homeostasis in Prediabetic Subjects (NA)
- Investigation of Milk Peptides (Pep2Dia®) on Postprandial Blood Glucose Profile in Prediabetic Subjects (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pep2dia CI brief — competitive landscape report
- pep2dia updates RSS · CI watch RSS
- Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy portfolio CI